BEAM - BEAM

Beam Therapeutics 株価情報 (NASDAQ: BEAM)

最新ニュース Beam Therapeutics (NASDAQ:BEAM) 株価情報

Beam Therapeutics

Beam Inc.

NYSE

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Beam Therapeutics Inc

BEAM - United States Dollar

BEAM COMM HLDGS LTD by BEAM COMMUNICATIONS HLDGS LTD.

Beam Global

Beamr Imaging Ltd

BEAMZ INTERACTIVE INC by Beamz Interactive Inc

Beamz Interactive Inc

News

BEAM

Beam Therapeutics Expects Cash Runway To Support Operating Plans Into 2027, Now Inclusive Of Commercial Readiness Activities For BEAM-101

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

On Saturday, Beam Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease (SCD) with severe <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42378289/beam-therapeutics-announces-new-data-from-beacon-phase-12-clinical-trial-of-beam-101-in-sickle-cel" rel="noreferrer noopener">vaso-occlusive crises (VOCs)</a>.
The data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition.
Consistent with Beam&#8217;s&nbsp;previously announced&nbsp;data, updated data from seven patients treated with investigational base-editing therapy BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis.
No VOCs were reported post-engraftment.
Key highlights include the following:
<ul>
<li>Rapid and Sustained Increases in Protective Fetal Hemoglobin (HbF): All patients achieved endogenous HbF levels exceeding 60% and reduction in corresponding sickle hemoglobin (HbS) below 40% that was durable. A pancellular distribution of HbF was observed after the elimination of transfused blood.</li>
<li>Robust and Sustained Total Hemoglobin (Hb) Levels: Total hemoglobin levels increased rapidly with a resolution of anemia in patients after the elimination of the transfused blood.</li>
<li>Normalization of Hemolysis Markers: Key markers of hemolysis, including indirect bilirubin, haptoglobin, lactate dehydrogenase and reticulocytes, normalized or improved in all patients following BEAM-101 treatment.</li>
<li>Safety Profile Consistent with Busulfan and Autologous Hematopoietic Stem Cell Transplantation.</li>
</ul>
In November, the company said that one patient died due to respiratory failure likely related to busulfan conditioning four months after BEAM-101 infusion. However, the investigator determined that the death was <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41756981/gene-therapy-developer-beam-therapeutics-reports-one-patient-death-in-early-stage-sickle-cell-dis" rel="noreferrer noopener">unrelated to BEAM-101</a>.
On Sunday, Beam Therapeutics announced new data for its Engineered Stem Cell Antibody Evasion (ESCAPE) conditioning platform, which was presented at the American Society of Hematology Annual <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42380675/beam-therapeutics-presents-new-non-human-primate-nhp-data-demonstrating-proof-of-concept-for-escap" rel="noreferrer noopener">Meeting and Exposition</a>.
ESCAPE comprises two investigational drug products, BEAM-103 and BEAM-104. The company intends to advance BEAM-103 and BEAM-104 for development in sickle cell disease and beta-thalassemia.
In the preclinical study, administration of the BEAM-104 edited cells to antibody-conditioned animals led to long-term engraftment.
Dosing with the BEAM-103 mAb led to rapid and near complete replacement of wild-type erythroid cells by edited cells, leading to early induction of therapeutically relevant levels of HbF.
BEAM-103 dosing was well tolerated, with no need for transfusions, antibiotics, or additional supportive care.
William Blair writes, &#8220;While the patient death is unfortunate, we see the event as highlighting the need for less-toxic preconditioning options, and we think Beam is leading the space in this regard.&#8221;
Price Action: At last check on Monday, BEAM stock was up 0.52% at $26.89.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42387962/palantir-scores-368-million-deal-with-ussocom-to-lead-ai-powered-mission-command" target="_blank" rel="noreferrer noopener">Palantir Jumps After Securing USSOCOM Contract Boost &#8211; What&#8217;s Going On?</a></li>
</ul>

Analyst Color

Biotech

Health Care

General

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

<ul>
<li>NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of&nbsp;Hemoglobin F</li>
<li>mAb Dosing Well Tolerated Without Need for Supportive Care</li>
<li>Beam on Track to Initiate Phase 1-enabling Studies by End of 2024</li>
</ul>

Reported Sunday, Beam Therapeutics Showcases Proof-Of-Concept Non-Human Primate Data For ESCAPE, A Non-Genotoxic Antibody-Based Conditioning Strategy For Sickle Cell Disease, At ASH 2024

<a href="https://www.globenewswire.com/Tracker?data=iLZ9x69dnGVH2dDnn_bqKdcRxuqSk8c9oR7gIU98LWWR7EKFfy8SYnFEVh3zx6Q_3ZtiiGoWRO5HH5TVXoK6RKufAiNiO3mNqfmZfC89hSY=">Beam Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), a biotechnology company developing precision genetic medicines through base editing, today announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). The data were featured today in the press program for the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and will be presented in an oral session on Sunday, Dec. 8, 2024, at 10 a.m. PT.
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of &gt;60%, Hemoglobin S (HbS) Reduction to &lt;40%, and Resolution of Anemia Post-BEAM-101 Treatment
Initial Safety Profile Consistent with Busulfan Conditioning and Autologous Hematopoietic Stem Cell Transplantation
All Seven Patients Dosed Achieved Target Cell Dose with One or Two Mobilization Cycles and Experienced Rapid Neutrophil and Platelet Engraftment
Markers of Hemolysis Normalized or Improved in All Patients

Beam Therapeutics Announced New Data from BEACON Phase 1/2 Clinical Trial Of BEAM-101 In Sickle Cell Disease at ASH Meeting; Said All Seven Patients Treated With BEAM-101 Achieved Hemoglobin F (HbF) Induction Of >60%, Hemoglobin S (HbS) Reduction To <40%, And Resolution Of Anemia Post-BEAM-101 Treatment

WIIM

Beam Therapeutics shares are trading higher. The company appointed a new CFO.

Management

Beam Therapeutics Has Appointed Sravan Emany As Chief Financial Officer, Effective December 19

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
What Happened: Wood&#8217;s enthusiasm centers on what she describes as a transformative convergence of technologies that could revolutionize medical treatment and drug discovery. 
Speaking candidly about the sector, Wood highlighted the remarkable progress in genetic therapies, particularly in companies like Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), and Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>).
Her most striking example involves Crispr Therapeutics&#8217; recent breakthrough in sickle cell disease treatment. Wood noted, referencing how patients who previously required 12 to 20 annual blood transfusions might now be free from such interventions.
The strategy extends beyond treatment breakthroughs to drug development itself. Wood points to companies like Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) as leveraging artificial intelligence to dramatically reduce clinical trial failure rates and accelerate drug development timelines.
However, the market performance of these innovative companies tells a more nuanced story. Year-to-date, the stocks have experienced significant volatility: Crispr Therapeutics is down 25.36%, Intellia Therapeutics has dropped 52.21%, Beam Therapeutics declined 3.04%, and Recursion Pharmaceuticals fell 9.80%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space. Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/42205763/disney-reaches-43m-settlement-in-gender-pay-discrimination-lawsuit-women-can-expect-equitable-treatment-moving-forward">Disney Reaches $43M Settlement In Gender Pay Discrimination Lawsuit: &#8216;Women Can Expect Equitable Treatment&#8217; Moving Forward</a>
Why It Matters: ARK&#8217;s commitment to this sector is evident through its Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>), which manages net assets of $1.179 billion. The fund&#8217;s performance reflects the sector&#8217;s volatility, with annual returns ranging from a high of 180.50% in 2020 to a low of -53.94% in 2022.
The ETF&#8217;s current top holdings underscore Wood&#8217;s strategic focus on innovative biological technologies. Twist Bioscience Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) leads the portfolio at 8.90%, followed by Crispr Therapeutics at 7.88% and Recursion Pharmaceuticals at 6.17%. Other significant investments include CareDx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), and Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), representing a diversified approach to genomic and biological innovation.
Wood&#8217;s vision suggests a potential $400 billion market opportunity in biologics over the next five years, driven by the unprecedented convergence of AI, sequencing technologies, and gene editing. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a></li>
</ul>
Image via Ark Invest
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

ADPT

ARKG

CDNA

CRSP

NTLA

RXRX

TWST

VCYT

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

BofA Securities downgraded Editas Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), citing few value-driving catalysts <a target="_blank" href="https://www.benzinga.com/quote/EDIT/analyst-ratings" rel="noreferrer noopener">in the near term</a>.
In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301).
The company is developing reni-cel for sickle cell disease and transfusion-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41710488/editas-medicine-announces-third-quarter-2024-results-and-business-updates" rel="noreferrer noopener">dependent Beta Thalassemia</a>.
The company is on track to share additional clinical and patient-reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology Annual Meeting in December.
The company has completed enrollment of the adult cohort of the EdiTHAL trial for thalassemia and continues patient dosing.
The analyst notes that Editas announced a shift in focus toward in vivo development, specifically working on lipid nanoparticle (LNP) formulations for treating sickle cell disease (SCD) and thalassemia.
While preclinical data shows some progress—29% editing in hematopoietic stem and progenitor cells (HSPCs) and around 20% of red blood cells expressing fetal hemoglobin (HbF)—more evidence is needed to prove functional benefits and advance to clinical trials.
Meanwhile, competitors like Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) and CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) are investing heavily in their in vivo programs for SCD and thalassemia, with better-prepared manufacturing and development for clinical trials.
Given the deprioritization of reni-cel and the increasingly competitive environment for ex vivo therapies, BofA has reduced estimates and probabilities of success in SCD and beta-thal to 10% (from 60% prior).
The analyst downgraded from Buy to Underperform, with a price target of $1, down from $13.
This intensifying competition, limited short-term clinical milestones, and declining interest in gene editing pose challenges for Editas and could pressure its stock in the near term.
Price Action: EDIT stock is down 0.41% at $2.43 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42168509/amd-teams-up-with-taiwan-semi-to-take-on-samsung-in-smartphone-market" target="_blank" rel="noreferrer noopener">AMD Teams Up With Taiwan Semi To Take On Samsung In Smartphone Market</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Downgrades

Trading Ideas

EDIT

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Sector Perform and lowers the price target from $27 to $24.

RBC Capital Maintains Sector Perform on Beam Therapeutics, Lowers Price Target to $24

Beam Therapeutics shares are trading higher after Leerrink Partners upgraded the stock from Market Perform to Outperform and raised its price target from $27 to $39.

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $47.8, a high estimate of $80.00, and a low estimate of $24.00. A 4.4% drop is evident in the current average compared to the previous average price target of $50.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1730901635_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Beam Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Bienkowski</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beam Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Beam Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Beam Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Beam Therapeutics analyst ratings.</a>
<h2>About Beam Therapeutics</h2>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Beam Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Beam Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -41.48%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Beam Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -773.45%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -10.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Beam Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -6.95%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Beam Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580f253b846faa000139ba71/robert-moskow">TD Cowen analyst Robert Moskow</a> upgraded the rating for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170. Clorox shares closed at $162.42 on Tuesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Trevor Young upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Underweight to Equal-Weight and raised the price target from $17 to $25. Revolve shares closed at $26.02 on Tuesday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/616e99feb650db000151570b/rick-bienkowski">Leerink Partners analyst Rick Bienkowski</a> upgraded the rating for Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and increased the price target from $27 to $39. Beam Therapeutics shares closed at $23.93 on Tuesday. <a href="https://www.benzinga.com/quote/BEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst David Begleiter upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowered the price target from $135 to $110. Celanese shares closed at $91.00 on Tuesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>

Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png" alt="" class="wp-image-632747" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49.png 1230w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Upgrades

Pre-Market Outlook

RVLV

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

Leerink Partners analyst Rick Bienkowski upgrades Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and raises the price target from $27 to $39.

Leerink Partners Upgrades Beam Therapeutics to Outperform, Raises Price Target to $39

On Tuesday, Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell therapy for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41745039/beam-therapeutics-to-present-data-across-hematology-franchise-including-first-clinical-data-for-be" rel="noreferrer noopener">sickle cell disease (SCD)</a>.
Eight of these patients have been dosed with BEAM-101, while the other enrolled patients are going through pre-transplant stages, including cell collection and drug product manufacturing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40375976/gene-editing-korro-bios-preclinical-data-best-in-class-analyst-initiates-with-outperform-rating" rel="noreferrer noopener">Gene Editing Korro Bio&#8217;s Preclinical Data &#8216;Best-In-Class&#8217;, Analyst Initiates With Outperform Rating</a>
In a company <a target="_blank" href="https://investors.beamtx.com/static-files/4e9eea51-c299-4b58-965a-87a5a8c3b62f" rel="noreferrer noopener">presentation</a>, preliminary safety data (N=6) showed an initial safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant (HSCT).
The company said that one patient died due to respiratory failure likely related to busulfan conditioning 4 months after BEAM-101 infusion. However, the investigator determined that the death was unrelated to BEAM-101.
The Data Safety Monitoring Committee and FDA reviewed the case.
In all patients dosed, there were no ≥ Grade 3 adverse events (AEs) or serious AEs related to BEAM-101.
Preliminary efficacy data showed that all patients achieved over 60% fetal hemoglobin (HbF, the main oxygen carrier protein in the human fetus) and less than 40% HbS (an abnormal type of hemoglobin that causes sickle cell disease) of non-transfused hemoglobin at Month 1, sustained through all time points.
Markers of hemolysis (destruction of red blood cells) normalized or improved for all patients.
No vaso-occlusive crises (VOCs, painful complication of sickle cell anemia) were reported by investigators following BEAM-101 treatment.
Beam Therapeutics said patient enrollment in the Phase 1/2 trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) is progressing. Site activation globally has continued, and dosing has been completed for the first cohort.
Beam has nominated a development candidate for its ESCAPE technology comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody (mAb), and BEAM-104, a cell therapy that includes the same therapeutic edit as BEAM-101 (editing the HBG1/2 genes to elevate fetal hemoglobin), plus an additional edit to CD117 which is designed to prevent binding of BEAM-103, allowing the edited cells to evade suppression by the antibody.
The company intends to advance BEAM-103 and BEAM-104 for development in SCD and beta-thalassemia.
Beam Therapeutics ended the third quarter of 2024 with $925.8 million in cash, cash equivalents, and marketable securities, providing a cash <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41739986/beam-therapeutics-reports-third-quarter-2024-financial-results-and-progress-across-priority-progra" rel="noreferrer noopener">runway into 2027</a>.
Price Action: BEAM stock is down 2.40% at $23.78&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation" target="_blank" rel="noreferrer noopener">Nvidia Takes Short-Lived Lead Over Apple In Valuation</a></li>
</ul>

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial

Highlights Also Include BEAM-201 CAR-T Therapy Data And Proof-Of-Concept For Non-Genotoxic Conditioning

Beam Therapeutics To Present Hematology Franchise Data At ASH Annual Meeting, Including First Clinical Data For BEAM-101 In Sickle Cell Disease And Preclinical ESCAPE Findings

Beam Therapeutics shares are trading lower in reaction to a report indicating a patient in the company's CRISPR-based sickle cell treatment trial died.

<a href="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss" title="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss">https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss</a>

Patient In Beam Therapeutics' CRISPR Trial For Sickle Cell Disease Dies From Likely Chemotherapy Complications; Early Signs Of Gene Editing Effectiveness Observed In Other Participants

Earnings

Guidance

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Editas cut to equal weight by Wells Fargo over reni-cel positioning

20:07 EST Cathie Wood's ARK Investment buys 116K shares of Beam Therapeutics (BEAM) today Published first on TheFly – the ultimate source for real-...

Cathie Wood's ARK Investment buys 116K shares of Beam Therapeutics today

Bernstein analyst William Pickering raised the firm's price target on Beam Therapeutics (BEAM) to $37 from $35 and keeps an Outperform rating on th...

Beam Therapeutics price target raised to $37 from $35 at Bernstein

Beam upgraded by Bernstein ahead of AATD data

Bernstein upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $37, up from $35. The firm, which believes the...

Beam Therapeutics upgraded to Outperform from Market Perform at Bernstein

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price targ...

Scotiabank Remains a Hold on Beam Therapeutics (BEAM)

William Blair analyst Sami Corwin has maintained their bullish stance on BEAM stock, giving a Buy rating on January 7. Sami Corwin's rating is base...

Beam Therapeutics: Strong Pipeline and Strategic Global Expansion Justify Buy Rating

Yanan Zhu, an analyst from Wells Fargo, reiterated the Buy rating on Beam Therapeutics (BEAM – Research Report). The associated price target remain...

Beam Therapeutics Positioned for Growth: Strong Pipeline and Financial Resilience Drive Buy Rating

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Beam Therapeutics (BEAM – Research Report) today and set a price targ...

Beam Therapeutics (BEAM) Gets a Hold from Bank of America Securities

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

BHVN

VRTX

Press Releases

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Comments

Beam Therapeutics

ニュース

最新ニュース Beam Therapeutics (NASDAQ:BEAM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル